Ghasemi Mehdi, Montaser-Kouhsari Laleh, Shafaroodi Hamed, Nezami Behtash Ghazi, Ebrahimi Farzad, Dehpour Ahmad Reza
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box, 13145-784, Tehran, Iran.
Psychopharmacology (Berl). 2009 Oct;206(2):325-33. doi: 10.1007/s00213-009-1609-1. Epub 2009 Jul 16.
In this study, we evaluated the involvement of N-methyl-D-aspartate receptor (NMDAR)/nitric oxide (NO) system on the antidepressant-like effects of paroxetine in the mouse forced swimming test.
Swim sessions were conducted by placing mice in individual glass cylinders filled with water for 6 min. The duration of behavioral immobility during the last 4 min of the test was evaluated.
Paroxetine (8 and 16 mg/kg, intraperitoneal [i.p.]) significantly reduced the immobility times of mice, whereas lower doses (2 and 4 mg/kg) had no effect. NMDA antagonists MK-801 (0.1 and 0.25 mg/kg, i.p.) and ifenprodil (1 and 3 mg/kg, i.p.) and the NO synthase inhibitor NG-L-arginine methyl ester (L-NAME; 30 and 100 mg/kg, i.p.) significantly decreased the immobility time. Lower doses of MK-801 (0.01 and 0.05 mg/kg), ifenprodil (0.1 and 0.5 mg/kg), and L-NAME (10 mg/kg) had no effect. Combined treatment of subeffective doses of paroxetine (4 mg/kg) and MK-801 (0.05 mg/kg), ifenprodil (0.5 mg/kg), and L-NAME (10 mg/kg) robustly exerted an antidepressant-like effect. The noneffective dose of a NO precursor L: -arginine (750 mg/kg, i.p.) prevented the antidepressant-like effect of paroxetine (30 mg/kg).
We suggested, for the first time, a possible role for NMDAR/NO signaling in the antidepressant-like effects of paroxetine, providing a new approach for the treatment of depression.
在本研究中,我们在小鼠强迫游泳试验中评估了N-甲基-D-天冬氨酸受体(NMDAR)/一氧化氮(NO)系统对帕罗西汀抗抑郁样作用的影响。
将小鼠置于装有水的单个玻璃圆筒中6分钟进行游泳试验。评估试验最后4分钟内行为不动的持续时间。
帕罗西汀(8和16毫克/千克,腹腔注射[i.p.])显著缩短了小鼠的不动时间,而较低剂量(2和4毫克/千克)则无作用。NMD A拮抗剂MK-801(0.1和0.25毫克/千克,腹腔注射)和艾芬地尔(1和3毫克/千克,腹腔注射)以及NO合酶抑制剂N G-L-精氨酸甲酯(L-NAME;30和100毫克/千克,腹腔注射)显著缩短了不动时间。较低剂量的MK-801(0.01和0.05毫克/千克)、艾芬地尔(0.1和0.5毫克/千克)和L-NAME(10毫克/千克)无作用。亚有效剂量的帕罗西汀(4毫克/千克)与MK-801(0.05毫克/千克)、艾芬地尔(0.5毫克/千克)和L-NAME(10毫克/千克)联合治疗产生了强大的抗抑郁样作用。NO前体L-精氨酸的无效剂量(750毫克/千克,腹腔注射)可阻止帕罗西汀(30毫克/千克)的抗抑郁样作用。
我们首次提出NMDAR/NO信号在帕罗西汀抗抑郁样作用中可能发挥作用,为抑郁症治疗提供了新途径。